TP53 and cancer: Based on the growing recognition that p53 regulates immune responses, we have studied SGT-53 for its ability to augment cancer immunotherapy in a number of syngeneic mouse models including tumors of the head and neck, glioblastoma and breast, lung, and kidney cancers [81,82,83].